What the FDA’s New Psychedelic Framework Actually Means for the Clinic
FDA's September 2026 NEJM framework for psychedelic drugs reshapes trial design, REMS requirements, and patient access for psilocybin and...
The Mitochondrial Switch That Makes Drugs Different From Food
New Nature Neuroscience data shows MCU inhibition blocks drug reward without touching natural reward circuits, a mechanistic breakthrough for...
Dronabinol for PTSD Nightmares Is Promising, and the Dual Diagnosis Question Changes Everything
A Nature Medicine RCT shows dronabinol cuts PTSD nightmares. For the 46% of PTSD patients who also carry a...
LSD Just Beat Phase 3 Twice. Now Comes the Hard Part.
Definium's DT120 cleared Phase 3 in both MDD and GAD. As a ketamine PI who's treated 30,000+ patients, here's...
GLP-1 Agonists Reduce AUD Hospitalizations — But Stopping Them Is a Clinical Decision We’re Not Ready For
Lancet Psychiatry data show GLP-1 agonists cut AUD hospitalizations, with protection lasting 182 days post-discontinuation. Here's what that means...
GLP-1s Are Cutting My AUD Patients’ Hospitalizations. Trial Designers Need to Know Why.
A Lancet Psychiatry study links GLP-1 receptor agonists to fewer AUD and SUD hospitalizations—but the post-discontinuation signal demands a...
GLP-1 Agonists Are Quietly Reducing Addiction Hospitalizations, But Only While Patients Take Them
A Lancet Psychiatry study shows GLP-1 agonists cut AUD and SUD hospitalizations, but the protection fades after stopping —...
The Serotonin Signal Hiding in Plain Sight Across Two Rapid-Acting Depression Treatments
A Bayesian PET re-analysis finds ketamine and ECT both upregulate 5-HT1B receptors, pointing to a shared biomarker that TRD...
The Patients We’ve Been Afraid to Treat: PTSD, Psychosis, and What the STAR Trial Just Proved
The STAR trial enrolled 305 psychosis-PTSD patients clinicians long excluded from trauma therapy. The safety and efficacy data should...
What a Single-Dose Synthetic Psychedelic Teaches Us About the Limits of Our TRD Trial Designs
A JAMA Psychiatry trial of inhaled mebufotenin in TRD shows rapid antidepressant response, and exposes critical gaps in how...